Novo Nordisk Foundation's €80M Grant Programme Backs Long-Term Science as Buyback and Analyst Upgrades Lift Stock

Novo Nordisk gains 1.29% but remains 29% below its record. Support from €80M foundation grants, HSBC/Danske upgrades, and semaglutide implant deal fuel recovery hopes.

Novo Nordisk ended the week with a 1.29% gain, closing at €43.32, supported by a combination of a substantial share repurchase programme, fresh analyst upgrades, and a string of pipeline developments. Yet beneath the surface, the stock remains 29.22% below its July 2025 record of €61.20, underscoring the long road back to full recovery after a punishing 12-month slide. Investors are drawing confidence from a broad set of catalysts — not least the Novo Nordisk Foundation’s decision to commit up to €80 million to nine research projects that stretch far beyond the company’s core GLP-1 business.

On the price front, the equity has rebounded 43.21% from its March 2026 trough of €30.25. Over 30 days it has gained 16.78%, though it is still 3.04% lower year-to-date. Technical signals point to a healthy upswing: the stock trades 9.64% above its 50-day moving average of €39.51 and 6.69% above the 200-day average of €40.60. The relative strength index of 66 indicates rising momentum without straying into overbought territory, while an annualised volatility of 30.23% shows that sharp swings remain the norm.

The Novo Nordisk Foundation, which holds a controlling interest in the pharmaceutical group, has awarded nine new grants under its Challenge Programme. The €80 million will support projects tackling fungal diseases, cardiometabolic conditions, soil health, and complex biological systems far from equilibrium. Each team can work for up to six years, emphasising fundamental research rather than short-term deliverables. A notable change for the 2026 edition is the opening of the programme to applicants from across Europe; each consortium must include two to four research groups, with at least one based at a Danish university, hospital, or non-profit. The foundation, established in 1924, has a mandate that ranges from infectious and cardiometabolic disease research to the green transition.

Meanwhile, analyst sentiment is improving. HSBC raised its target from 280 to 300 Danish kroner while retaining a "Hold" rating, and Danske Bank stood out with a price target of 365 kroner and a buy recommendation. The broader consensus from 14 analysts polled by S&P Global averages $46.72, with a span from $39.56 to $64.19, and the majority classify the stock as a buy.

Novo Nordisk is also broadening its therapeutic arsenal. A non-exclusive agreement with Vivani Medical will allow the company to evaluate NPM-139, a semaglutide implant using Vivani’s NanoPortal technology. The deal carries no upfront payment, milestones, or royalties; Vivani plans to launch a first-in-human clinical study by mid-2026, using Wegovy injections as a comparator. More immediately, the oral version of Wegovy has reached private patients in the UK, priced at £69 for a starter pack and £189 for the monthly maximum dose. The National Health Service is not covering the cost. Clinical data show weight loss of up to 17% over 52 weeks, and the British medicines regulator has simultaneously expanded semaglutide’s approval to include advanced liver fibrosis. In the US, the oral tablet has already generated over three million prescriptions in just five months, mostly among first-time users.

Competitive pressure remains fierce, particularly in South Korea, where Eli Lilly has made aggressive inroads. Lilly’s Mounjaro recorded around 323.2 billion won in first-quarter sales in the country, while Wegovy managed only 104 billion won — roughly a third of that figure. Novo Nordisk’s Korean subsidiary has responded by merging its diabetes and obesity divisions this month, a move industry observers see as a direct counter to Lilly’s push.

Supporting the stock from a financial standpoint, the buyback programme has been running since 4 February 2026. Novo Nordisk has repurchased approximately 23 million B-shares at an average price of 270.32 kroner, spending about 6.2 billion kroner. The company now holds nearly 40.2 million of its own B-shares, equivalent to 0.9% of share capital. The programme has a total envelope of 15 billion kroner and runs for up to 12 months.

With the next quarterly report due in early August, market participants will be watching for operational trends in GLP-1 prescriptions and pipeline progress that could justify the recent rally. The foundation’s long-term research grants do not provide a near-term earnings boost, but they reinforce the scientific bedrock on which Novo Nordisk’s future growth is built — a message that, combined with the buyback and analyst upgrades, is helping steady the ship after a tumultuous year.